Semaglutide · research summary

Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.

Frontiers in endocrinology · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative review
“This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes.”

Subjects

Adults with obesity without established diabetes, including those with normoglycemia or prediabetes
“This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes.”

Reported findings

No prospective studies have established whether CGM-derived metrics precede or predict weight regain or whether CGM-guided interventions improve long-term weight-maintenance outcomes.
“However, no prospective studies have established whether CGM-derived metrics precede or predict weight regain, nor whether CGM-guided interventions improve long-term weight-maintenance outcomes in this setting.”
Validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have not been defined.
“Moreover, validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have yet to be defined.”
CGM-guided post-pharmacotherapy care remains investigational and requires prospective validation.
“CGM-guided post-pharmacotherapy care, therefore, remains investigational and requires prospective validation.”

Limitations stated by the authors

The supporting evidence is indirect and heterogeneous, and none of the groups directly represents the primary target population of adults with obesity without diabetes after discontinuation of incretin-based therapy.
“The supporting evidence is indirect and heterogeneous, encompassing adults without diabetes, individuals with prediabetes or type 2 diabetes. None of these groups directly represents the primary target population of adults with obesity without diabetes after discontinuation of incretin-based therapy.”

Source: PubMed 42865881 · DOI 10.3389/fendo.2026.1892632 · all study summaries

Subjects

Adults with obesity without established diabetes, including those with normoglycemia or prediabetes

“This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes.”

Reported findings

No prospective studies have established whether CGM-derived metrics precede or predict weight regain or whether CGM-guided interventions improve long-term weight-maintenance outcomes.

“However, no prospective studies have established whether CGM-derived metrics precede or predict weight regain, nor whether CGM-guided interventions improve long-term weight-maintenance outcomes in this setting.”

Validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have not been defined.

“Moreover, validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have yet to be defined.”

CGM-guided post-pharmacotherapy care remains investigational and requires prospective validation.

“CGM-guided post-pharmacotherapy care, therefore, remains investigational and requires prospective validation.”

Limitations stated by the authors

The supporting evidence is indirect and heterogeneous, and none of the groups directly represents the primary target population of adults with obesity without diabetes after discontinuation of incretin-based therapy.

“The supporting evidence is indirect and heterogeneous, encompassing adults without diabetes, individuals with prediabetes or type 2 diabetes. None of these groups directly represents the primary target population of adults with obesity without diabetes after discontinuation of incretin-based therapy.”